- Home
- ADAP vs HLVX Comparison
ADAP vs HLVX Comparison
Compare ADAP & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- HLVX
- Stock Information
- Founded
- ADAP 2008
- HLVX 2020
- Country
- ADAP United Kingdom
- HLVX United States
- Employees
- ADAP 506
- HLVX N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- HLVX Health Care
- Exchange
- ADAP Nasdaq
- HLVX Nasdaq
- Market Cap
- ADAP 75.5M
- HLVX 83.7M
- IPO Year
- ADAP 2015
- HLVX 2022
- Fundamental
- Price
- ADAP $0.29
- HLVX $1.90
- Analyst Decision
- ADAP Strong Buy
- HLVX Hold
- Analyst Count
- ADAP 5
- HLVX 5
- Target Price
- ADAP $1.83
- HLVX $2.33
- AVG Volume (30 Days)
- ADAP 777.8K
- HLVX 295.3K
- Earning Date
- ADAP 05-13-2025
- HLVX 05-08-2025
- Dividend Yield
- ADAP N/A
- HLVX N/A
- EPS Growth
- ADAP N/A
- HLVX N/A
- EPS
- ADAP N/A
- HLVX N/A
- Revenue
- ADAP $178,032,000.00
- HLVX N/A
- Revenue This Year
- ADAP N/A
- HLVX N/A
- Revenue Next Year
- ADAP $69.81
- HLVX N/A
- P/E Ratio
- ADAP N/A
- HLVX N/A
- Revenue Growth
- ADAP 195.34
- HLVX N/A
- 52 Week Low
- ADAP $0.20
- HLVX $1.34
- 52 Week High
- ADAP $1.48
- HLVX $16.31
- Technical
- Relative Strength Index (RSI)
- ADAP 51.38
- HLVX 60.50
- Support Level
- ADAP $0.30
- HLVX $1.81
- Resistance Level
- ADAP $0.32
- HLVX $1.94
- Average True Range (ATR)
- ADAP 0.02
- HLVX 0.10
- MACD
- ADAP 0.01
- HLVX 0.00
- Stochastic Oscillator
- ADAP 67.44
- HLVX 79.31
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.